Discussion
breast cancer
BREAST CANCER
In this phase II, open-label study, treatment with pamiparib demonstrated encouraging and durable clinical activity in patients with locally advanced or metastatic HER2− breast cancer harboring gA higher percentage of patients in this study received prior platinum-based chemotherapy compared with the OlympiAD and EMBRACA studies [The distribution of gThe safety profile of pamiparib was considered acceptable and was consistent with the overall safety profile of pamiparib in previous studies, and the safety profile of other PARPi [To the best of our knowledge, this is one of the largest studies conducted in Chinese women with locally advanced or metastatic HER2− breast cancer harboring g